SkinBioTherapeutics (LON:SBTX) Issues Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) released its quarterly earnings data on Monday. The company reported GBX (0.31) EPS for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Price Performance

SBTX stock opened at GBX 12.83 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57. The firm’s 50-day moving average price is GBX 15.49 and its two-hundred day moving average price is GBX 16.06. The stock has a market capitalization of £33.19 million, a price-to-earnings ratio of -10.26 and a beta of 2.01. SkinBioTherapeutics has a 12-month low of GBX 12 and a 12-month high of GBX 27.50.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.